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IL-15: A Pleiotropic Cytokine with Minireview
Diverse Receptor/Signaling Pathways Whose
Expression Is Controlled at Multiple Levels
Yutaka Tagaya, Richard N. Bamford, IL-2 is primarily produced by activated T cells,
Andrew P. DeFilippis, and Thomas A. Waldmann whereas there is no IL-15 mRNA demonstrable in normal
Metabolism Branch, National Cancer Institute resting or activated T cells as assessed by Northern blot
National Institutes of Health analysis. Nevertheless, there is widespread expression
Bethesda, Maryland 20892 of IL-15 message, which appears most abundantly in
placenta and skeletal muscle but also in kidney, lung,
and heart as well as lipopolysaccharide (LPS)-activated
Intercellular communications essential for regulatory monocytes (Grabstein et al., 1994; Bamford et al., 1996).
and effector actions involved in immune responses are The expression of the cytokine IL-2 is controlled pre-
often mediated by a series of proteins termed cytokines. dominantly at the level of transcription and message
Cytokines exhibit a high degree of redundancy and stabilization. In contrast, the synthesis and secretion of
pleiotropy, controlling a wide range of functions in vari- IL-15 appears to be controlled at multiple levels (e.g.,
ous cell types. The redundancy is explained in part by translation, and entry into secretory pathway) in addition
the promiscuity of receptors; that is, by the sharing of to transcription (Bamford et al., 1996). An additional dif-
common receptor subunitsamong members of thecyto- ference between IL-15 and IL-2 is that IL-15 uses a
kine receptor family (Bazan, 1990; Sato and Miyajima, distinct receptor and signaling system in select cells. In
1994; Kishimoto et al., 1994). Each cytokine has its own particular, IL-15 stimulates the proliferation of mast cells
private receptor but may also share a public receptor that do not respond to IL-2 (Tagaya et al., 1996). In
with other cytokines. For example, receptors for in- such cells, IL-15 binding and signaling involves a novel
terleukin-6 (IL-6), leukemia inhibitory factor, oncostatin receptor system that does not share any subunits with
M, ciliary neurotropic factor, IL-11, and cardiotropin-1 the IL-2R system. Furthermore, this novel IL-15R system
share a gp130 signaling unit, whereas IL-3, IL-5, and utilizes a signal transduction pathway distinct from the
granulocyte/macrophage colony-stimulating factor uti- one used by the IL-2/IL-15R system in T cells.
lize a common bc receptor subunit (Sato and Miyajima
1994, Kishimoto et al. 1994). There is a similar sharing Discovery of IL-15
of receptor elements within the IL-2 receptor (IL-2R) IL-15 was discovered because of the capacity of culture
system, a system that involves a, b, and g subunits
supernatants from two cell lines, CV-1/EBNA and the
(Noguchi et al., 1993a; Kondo et al., 1993). This sharing
HTLV-1-associated HuT-102, to stimulate proliferation
of IL-2R subunits was anticipated by the initially para-
of the cytokine-dependent murine T cell line CTLL-2
doxical observations that the immune system of mice
(Burton et al., 1994; Bamford et al., 1994; Grabstein et
made deficient in IL-2 by homologous recombination
al., 1994). The HTLV-1-associated HuT-102 adult T cell
developed relatively normally during the first few weeks
leukemia cell line was shown to secrete a 14±15 kDa
of life, whereas a mutation preventing the expression of
lymphokine, originally designated IL-T, that stimulates
the IL-2R g chain in humans resulted in X chromosome±
T cell proliferation and induces activation of NK cells
linked severe combined immunodeficiency disease
(Burton et al., 1994; Bamford et al., 1994). Simultane-
(X-SCID) (Schorle et al., 1991; Noguchi et al., 1993b). It
ously, a cytokine reported and designated IL-15 was
was subsequently demonstrated that IL-2Rg is not only
isolated from the supernatant solutions of the culturedan essential element of high and intermediate affinity
simian kidney epithelial cell line, CV-1/EBNA (Grabsteinreceptors for IL-2 but also is required for the actions of
et al., 1994). IL-15 shared many characteristics with IL-T,IL-4, IL-7, and IL-9.
including an apparent molecular mass of 14±15 kDa asRecently, a novel cytokine, IL-15, was defined whose
well as a signaling pathway in T and NK cells utilizingaction on T and natural killer (NK) cells requires the
the b and gc subunits of the IL-2R. By the use of anti-expression of both IL-2Rb and IL-2Rg (gc) (Burton et al.,
cytokine antibodies, IL-T and IL-15 were subsequently1994; Bamford et al., 1994; Grabstein et al., 1994). There
shown to be identical (Bamford et al., 1995, 1996).are many features shared by IL-2 and IL-15, including
the facts that both are members of the four a helix
The Structure of IL-15 and Itsbundle cytokine family (Figure 1), both utilize IL-2Rb and
Genomic Architecturegc for their action in T cells and, as anticipated by this
The cDNA defining IL-15 encodes a 162 aa peptide withreceptor sharing, both have similar functional activities
a 48 aa leader sequence yielding a 114 aa mature proteinwhen added to T, NK, and B cells (Grabstein et al.,
(Grabstein et al., 1994). There is 97% sequence identity1994; Burton et al., 1994; Bamford et al., 1994) (Table 1).
between human and simian IL-15 and 73% identity be-Indeed, it was not clear initially why two such apparently
tween human and murine IL-15. Although there is noredundant cytokines are produced. However, further
significant sequence homology between IL-2 and IL-15,analysis revealeddifferences between the two cytokines
analysis of the predicted secondary structure of IL-15in terms of theircellular sitesof synthesis, the role played
reveals that, like IL-2, it is a member of the short chainby posttranscriptional regulation in the control of cyto-
four a helix bundle cytokine family (Figure 1). Two disul-kine expression, and in the specific receptors and sig-
fide cross-links are present at Cys42±Cys88 (homolo-naling pathways utilized. For example, there are marked
gous to IL-2) and Cys35±Cys91.contrasts when the levels of regulation and sites of cyto-
kine expression of IL-15 and IL-2 are considered. Human IL-15 cDNA contains a 316 nt 59 untranslated
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exon±intron organization contrasts with the 4 exon/3
intron architectural pattern observed with IL-2, sug-
gesting that there is no significant evolutionary relat-
edness between these two genes. The cellular distribu-
tion of IL-15 mRNA and its translated protein will be
discussed below in the context of a consideration of
the regulation of IL-15 transcription, translation, and in-
tracellular trafficking.
The IL-15R System in T and NK Cells
Because of the functional similarities between IL-15 and
IL-2, it was anticipated that IL-15 might utilize subunits
of the IL-2R for binding and signal transduction (Bam-
ford et al., 1994; Grabstein et al., 1994; Giri et al. 1994).
The multisubunit IL-2R involves three independently
regulated subunits: the 55 kDa IL-2Ra (Tac peptide), the
70/75 kDa IL-2Rb, and the 64 kDa IL-2Rg (gc) subunits.
IL-2Rb and gc are members of the large hematopoietin
or cytokine receptor family. While IL-2Ra does not ap-
pear to be required for either binding or signaling medi-
ated by IL-15, the IL-2Rb and gc subunits of IL-2R are
required for the action of IL-15 on activated T and NK
cells (Bamford et al., 1994; Grabstein et al., 1994; Giri
et al., 1994). This conclusion derives from studies using
antibodies directed against various subunitsof the IL-2R
complex and those using cells transfected with different
IL-2R subunits (Bamford et al., 1994; Grabstein et al.,
1994; Giri et al., 1994).
Figure 1. Ribbon Diagram Showing Structural Features Common to
Thus, in T cells IL-2Rb is utilized by both IL-15 andthe Four a Helix Bundle Cytokine Family
IL-2 and gc is utilized by IL-15, IL-2, IL-4, IL-7, and IL-9.
The four helices are designated A, B, C, and D. The up±up±down±
One major clinical corollary that can be derived from thisdown topology refers to the fact that helices A and B point up, while
demonstration of sharing of receptor subunits amonghelices C and D point down. (Figure reproduced with permission
from Rozwarski et al., 1994, Current Biology 2 159±173). different cytokines is that therapy directed toward
shared receptor subunits or a molecule such as Jak3
that is associated with the membrane receptor-proximal
signaling events of all receptor systems that utilize gcregion (UTR), a coding sequence of 486 nt, and a 400
nt 39 UTR (Grabstein et al., 1994). The human IL-15 gene may lead to effects that differ from those observed with
therapeutic agents that inhibit the synthesis of an indi-was mapped to chromosome 4q31 by fluorescence in
situ hybridization (Anderson et al., 1995a). The murine vidual cytokine. For example, IL-2Rb-, gc-, or Jak3-di-
rected therapy may yield more profound immunosup-IL-15 gene that consists of 8 exons and 7 introns span-
ning at least 34 kb was localized to the central region pression than can be achieved by the inhibition of the
synthesis of either IL-2 or IL-15 alone.of mouse chromosome 8 (Anderson et al., 1995a). This
Table 1. Comparison of Human IL-15 and IL-2
Properties IL-15 IL-2
Structure of cytokine 14±15 kDa, 114 aa 14±15 kDa, 133 aa
Four helical bundle cytokine Four helical bundle cytokine
Genomic structure 8 exon/7 intron 4 exon/3 intron
Cellular distribution of Expressed in placenta, skeletal muscle, Predominantly activated T cells
mRNA Expression kidney, lung, heart, fibroblasts,
epithelial cells, and activated
monocytes.
Not expressed by T cells.
Regulation of cytokine Transcription, translation, and Transcription and message stabilization.
expression possibly intracellular trafficking. Simple 59 UTR with no upstream
Complex 59 UTR with 10 upstream AUGs. 20 aa signal peptide.
AUGs. 48 aa signal peptide.
Receptor in T and NK cells IL-15Ra, IL-2Rb, gc IL-2Ra, IL-2Rb, gc
Receptor in mast cells IL-15RX Does not stimulate mast cells
JAK/STAT signal transduction Jak1/Jak3 Jak1/Jak3
pathway in T cells Stat3/Stat5 Stat3/Stat5
JAK/STAT signal transduction Jak2 Does not stimulate mast cells
pathway in mast cells Stat5
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Several observations suggested the existence of one activated vascular endothelial cells (Giri et al., 1995). IL-
or more specific IL-15R proteins in addition to IL-2Rb 15Ra mRNA expression was increased in T cells follow-
and gc (Giri et al., 1995). For example, many non- ing addition of IL-2 or of a CD3 antibody plus phorbol
lymphoid cell types bind IL-15 but not IL-2. Furthermore, myristyl acetate. Furthermore, IL-15Ra expression was
Epstein±Barr virus immortalized B cell lines from pa- augmented in macrophage cell lines following their
tients with X-SCID who have a defect in gc expression treatment with interferon-g (IFNg) (Giri et al., 1995). Thus,
bind IL-15 with high affinity (Giri et al., 1995; Kumaki et the widespread distribution of the elements (IL-15Ra,
al., 1995). This binding is unlikely to be due solely to IL-2Rb, and gc) of the IL-15R system is one of the mech-
IL-2Rb, since this subunit when expressed alone in anisms that underlies the pleiotropy of IL-15; that is, its
transfected COS-7 cells did not bind detectable quanti- ability to exert an action on multiple cell types.
ties of IL-15. Stimulated by these observations, a novel
IL-15-binding protein termed IL-15Ra was identified and IL-15 Signal Transduction Pathway
its cDNA was cloned (Giri et al., 1995). IL-15Ra is a type in Activated T Cells
1 membrane protein with a predicted signal peptide of Signal transduction pathways that involve Janus-asso-
32 aa, a 173 aa extracellular domain, a single membrane ciated kinases (JAKs) and signal transducers and activa-
spanning region of 21 aa, and a 37 aa cytoplasmic do- tors of transcription (STATs) are utilized by a number of
main. IL-15Ra is not a member of thecytokine superfam- growth factors and cytokines that bind to members of
ily. However, it showed fragmentary sequence matches the cytokine receptor family (Witthuhn et al., 1994; John-
with IL-2Ra. Detailed comparisons of IL-15Ra with IL- ston et al., 1995). When analyzed in activated T cells,
2Ra revealed the shared presence of a conserved bind-
Jak3 and Jak1 were shown to be coupled functionally
ing motif, the GP-1 motif or short consensus repeat
to the receptor systems that involve gc including the
(SCR) or ªSushiº domain (Giri et al., 1995). Other proteins
receptors for IL-15, IL-2, IL-4, IL-7, and IL-9 (Figure 2).
sharing this motif include C1s, C1r, C4BP, factor VIII,
Furthermore, the addition of IL-15 or IL-2 to such recep-
factor B, and factor H. IL-15Ra was viewed as structur-
tor-expressing T cells lead to tyrosine phosphorylationally similar to IL-2Ra, so that together they define a new
and nuclear translocation of Stat3 and Stat5 (Lin et al.,
cytokine receptor family (Giri et al., 1995). This view is
1995). The IL-2 and IL-15 signaling pathways in T cellssupported by the recent observation that IL-15Ra and
also involve the phosphorylation of the src-related cyto-IL-2Ra have a similar intron±exon organization and that
plasmic tyrosine kinases p56lck and p72syk, the inductionthese genes are closely linked inboth human (10q 14±15)
of the expression of the Bcl-2 anti-apoptotic pathway,and murine genomes (chromosome 2 linked to Vim1 and
as well as the stimulation of the Ras/Raf/MAP kinaseSpna2) (Anderson et al., 1995b).
pathway leading to Fos/Jun activation (Miyazaki et al.,IL-15Ra binds IL-15 with an affinity approximating
1995).1 3 1011M21, a 1,000-fold higher affinity than that of IL-
2Ra for IL-2 (Giri et al., 1995). However, like IL-2Ra,
IL-15 Utilizes a Novel Receptor/SignalIL-15Ra does not appear to participate in IL-15 signal
Transduction Pathway in Mast Cellstransduction (Anderson et al., 1995b). IL-15Ra mRNA
As part of an effort to define a function of IL-15 notexpression has a much wider cellular distribution than
shared with IL-2, it was demonstrated that murine mastIL-2Ra message. IL-15Ra mRNA expression was ob-
cell lines and normal bone marrow mast cells proliferateserved in T cell, B cell, macrophage, thymic, and bone
in response to IL-15 but not to IL-2 (Tagaya et al., 1996).marrow stromal cell lines. In addition, there was a wide-
This disparity in response to the two cytokines sug-spread tissue distribution of IL-15Ra mRNA that in-
cluded liver, heart, spleen, lung, skeletal muscle, and gested the existence of a novel IL-15-specific receptor
Figure 2. Diagram of Two IL-15 Receptor/
Signaling Systems
(A) The T cell IL-15R includes IL-15Ra, IL-2/
IL-15Rb, and gc subunits. The signal trans-
duction pathway of this multisubunit receptor
involves the activation of Jak1 and Jak3 as
well as the tyrosine phosphorylation and nu-
clear translocation of Stat3 and Stat5.
(B) The mast cell IL-15R does not involve
known components of the T cell IL-15R sys-
tem. However, mast cells express a novel
60±65 kDa IL-15R, provisionally designated
IL-15RX. The membrane proximal events of
IL-15 signal transduction involve Jak2 and
Stat5 instead of the Jak1/Jak3 and Stat3/
Stat5 that are utilized by T cells.
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system on mast cells not shared with IL-2. To examine and bone marrow stromal cells suggests a possible role
for IL-15 in the differentiation and maturation of the cellsexpression of individual IL-2R components in the murine
mast cell lines, RT±PCR analysis was carried out using of the immune system. Finally, the broad expression of
messenger RNA encoding IL-15 and its IL-15Ra receptorcDNAs from the mast cell lines PT-18 and MC/9 as
templates. These cells did not express mRNA encoding subunit compared with the expression of IL-2 and its
specific IL-2Ra receptor suggests that IL-15 has activi-IL-2Ra or IL-2Rb. Furthermore, by transfecting these
cells with a cytoplasmic-truncated transdominant mu- ties beyond the immune system. An example of such
nonimmune cell action is noted with skeletal musclestant of gc, it was demonstrated that IL-15 signaling in
mast cells does not require this receptor element (Ta- that express mRNA encoding IL-15 and its receptor
(Quinn et al., 1995). The addition of IL-15 to a culturedgaya et al., 1996). In addition, there is evidence sug-
gesting that IL-15Ra is not a critical element of the mast myoblast cell line did not induce proliferation, but af-
fected parameters associated with skeletal muscle fibercell IL-15R and signaling pathway.
To identify a possible mast cell±specific IL-15R pro- hypertrophy in such cells, suggesting that IL-15 may be
an anabolic agent that increases skeletal muscle masstein, 125I±IL-15 was cross-linked to the mast cell line PT-
18 using disuccinimidyl suberate (DSS). The IL-15/IL- (Quinn et al., 1995). Other actions beyond the immuno-
logical system are suggested by the demonstration that15R complex migrated around 75±80 kDa, implying a
cytokine receptor size of 60±65 kDa. This complex mani- mRNAs for IL-15 and its receptor are expressed by other
tissues including the kidney, lung, liver, epithelial cellfested faster migration in the gel than complexes com-
posed of IL-15 and the known components of the IL- lines, and activated endothelial cells. Finally, as dis-
cussed above, mast cells express an IL-15 receptor15R system that are present in CTLL-2 T cells. These
results suggest that mast cells express a novel 60±65 signaling pathway that is distinct from that used by IL-2
and IL-15 in activated T cells (Tagaya et al., 1996). ThiskDa IL-15R molecule, which was provisionally desig-
nated IL-15RX (Figure 2; Tagaya et al., 1996). intermediate affinity IL-15R on mast cells may have a
functional role in mast cell biology in that IL-15 mayAs noted above, the membrane-proximal events of
IL-15 signal transduction in activated T cells involve the complement the actions of IL-3 and stem cell factor in
the differentiation of mast cells from their precursors.tyrosine phosphorylation of Jak1/Jak3 and Stat3/Stat5
(Johnston et al., 1995; Lin et al., 1995). In contrast, in In addition, IL-15 may be involved in activation of resting
mast cells into effector cells with the induction of themast cell lines the novel IL-15R recruits Jak2 and Stat5
(Figure 2; Tagaya et al., 1996). These IL-15-induced pro- expression of cytokines and chemical mediators con-
tained in mast cell granules. Finally, IL-15 stimulatesliferative responses and receptor signaling pathways
were also observed with normal bone marrow mast cells mast cell proliferation in vitro and ex vivo (Tagaya et al.,
1996), and IL-15 may control activation and proliferation(Tagaya et al., 1996). These results indicate that there
exists an IL-15 function distinct from that of IL-2, in that of normal mast cells as well as the pathological propaga-
tion of mast cells that leads to mastocytosis.mast cells appear to utilize a novel IL-15R that does not
share any subunits with the IL-2R system, and that this
novel IL-15R recruits a JAK/STAT signal transduction
Regulation of IL-15 Expressionpathway distinct from the one used by the IL-2R/IL-15R
IL-15 differs dramatically from IL-2 in terms of the cellu-system in T cells. These observations that demonstrate
lar distribution of its message and in terms of the multi-the existence of two distinct IL-15 receptor/signaling
plicity of levels of control of the synthesis and secretionpathways in different cells identify a second mechanism
of this cytokine. In particular, in contrast with the pre-that underlies the pleiotropy manifested by IL-15 inaddi-
dominantly T cell pattern of expression of IL-2 message,tion to the widespread tissue distribution of IL-15Ra
IL-15 mRNA could not be demonstrated in normal rest-discussed above.
ing or phytohemagglutinin-activated T cells (Grabstein
et al., 1994; Bamford et al., 1996). However, on Northern
blot analysis there was widespread expression of IL-15The Functions of IL-15
IL-15 shares a number of biological activities with IL-2, mRNA in other cells, most abundantly in placenta and
skeletal muscle but also in kidney, lung, heart, fibro-including stimulation of the proliferation of activated
CD41, CD81, as well as the gd subsets of T cells blasts, epithelial cells, and monocytes (Grabstein et al.,
1994; Bamfordet al., 1996). IL-15expression is regulated(Grabstein et al., 1994). IL-15 also stimulates the prolifer-
ation of NK cells and acts as a costimulator with IL-12 in part at the level of transcription. For example, IL-15
mRNA levels are increased by ultraviolet B irradiation ofto facilitate the production of IFNg and tumor necrosis
factor-a by these cells (Carson et al., 1994). IL-15 addi- keratinocytes (Mohamadzadeh et al., 1995), by Herpes
virus-6 infection of monocytes (Flamand et al., 1996),tion also promotes the induction of cytolytic effector
cells, including cytotoxic T cells and lymphokine acti- and by LPS/IFNg activation of monocytes (Grabstein et
al., 1994; Bamford et al., 1996).vated killer cells (Grabstein et al., 1994), and it acts as
a potent T cell chemoattractant (Wilkinson and Liew, The concentrations of most cytokine molecules are
determined at the level of message transcription and1995; McInnes et al., 1996). Furthermore, IL-15 induces
proliferation and immunoglobulin synthesis by human stabilization. Consequently, it hasusually beenassumed
that a high cellular level of IL-15 mRNA expression willtonsillar B cellsstimulated by CD40 ligand or an immobi-
lized antibody to immunoglobulin M (Armitage et al., universally yield large quantities of secreted IL-15. How-
ever, this does not appear to be a valid assumption.1995). The demonstration of IL-15 and IL-15R message
in fetal tissues including fetal liver, thymic epithelium, Although IL-15 message is widely expressed, it has been
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difficult to demonstrate IL-15 in the supernatants of long (48 aa) IL-15 signal peptide. Insights into the effect
of the IL-15 signal peptide on synthesis and secretionmany cells that express message for this cytokine. This
also applies to cells transfected with IL-15 encoding of IL-15 were gained by generating constructs linking
the mature IL-15 protein coding sequence to the IL-2cDNA. In particular, although peripheral blood mononu-
clear cells activated with LPS/IFNg express high levels signal peptide and reciprocally linking the IL-15 signal
peptide to the IL-2 mature protein coding sequence.of mRNA encoding IL-15, their culture supernatants did
not contain meaningful quantities of IL-15 as assessed The quantity of IL-2 synthesized (i.e., the sum of cell-
associated and secreted IL-15) by transfected COS cellsby either the CTLL-2 proliferation assay or by an IL-15-
specific enzyme-linked immunosorbent assay (Bamford was reduced by as much as 50-fold when the sequence
encoding the IL-2 signal peptide was replaced by thatet al., 1995, 1996). This suggests that normal IL-15 pro-
duction and secretion are regulated at levels in addition of IL-15. On the other hand, the quantity of IL-15 synthe-
sized increased approximately 20-fold when its signalto the controls of transcription and message stabiliza-
tion that regulate the expression of other cytokines such peptide was replaced by that of IL-2. Thus, the unusual
IL-15 signal peptide appears to contribute to the ineffi-as IL-2.
Discordance between IL-15 message expression and ciency of IL-15 synthesis and secretion. Clearly, other
components of the IL-15 message (e.g., those that en-IL-15 synthesis and secretion stimulated an examination
of normal IL-15 mRNA for posttranscriptional controls, code the mature IL-15 protein sequence or the 39 UTR)
must be examined for additional elements that mightparticularly for features that would inhibit IL-15 produc-
tion at the level of mRNA translation (Bamford et al., regulate the rates of IL-15 translation and secretion.
1996). Initial studies focused on the 59 UTR of IL-15
mRNA. In general, the 59 UTRs of effectively translated
Aberrant IL-15 Transcription and Translationmessages are short, simple, and unencumbered by
Underlies the Effective IL-15 Production by theAUGs upstream of the initiation AUG. In contrast with
HTLV-1-Associated ATL Cell Line HuT-102this pattern, the 59 UTR of IL-15 message is long (316 nt
The HTLV-1-associated ATL cell line HuT-102 that pro-in humans, 465 nt in mice), quite complex, and includes
duces IL-15 was examined to gain further insights con-multiple upstream AUGs (10 in humans, 5 in mice)
cerning the control of IL-15 synthesis and secretion(Grabstein et al., 1994; Bamford et al., 1996).
(Bamford et al., 1996). This efficient synthesis and secre-The presence of such upstream AUGs in the 59 UTR
tion of IL-15 could not have been predicted on the basisof mRNAs may dramatically reduce the efficiency of
of other studies of IL-15 mRNA expression. HuT-102 istheir translation (Kozak, 1987). Among the other four a
a T cell line, yet normal resting or activated T cells dohelix bundle cytokines, no upstream AUGs were present
not express IL-15 mRNA as assessed by Northern blotin the 59 UTR of IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-
analysis. Furthermore, HuT-102 is quite effective in syn-13, G-CSF, GM-CSF, or IFNg, but were seen with IL-7
thesizing and secreting IL-15 in contrast with many nor-(Kozak, 1991). In general, messages with 59 AUG-bur-
mal resting and activated cells. The research involveddened untranslated sequences include those encoding
a comparison of the IL-15 mRNA derived from HuT-102many proto-oncogenes, transcription factors, a variety
with that of normal activated monocytes (Bamford etof receptor proteins, and signal transduction compo-
al., 1996). When compared with activated monocytes,nents. Inhibition of translation by upstream AUGs has
IL-15 mRNA expression was 6- to 10-fold greater in HuT-been confirmed experimentally by deletion of upstream
102 cells. The predominant IL-15 message from HuT-AUGs or by site-directed mutagenesis of the AUG trip-
102 was a chimeric mRNA joining a 118 nt segment oflets in TGFb3, FGF-5, and IL-7 messages (Arrick et al.,
the R region of the long terminal repeat of HTLV-1 to1991; Bates et al., 1991; Namen et al., 1988). Such up-
the 59 UTR of IL-15 (Bamford et al., 1996; Figure 3).stream AUG codons may represent a ploy by the cell
Normally, by alternative splicing this 118 nt element ofto yield poorly translated messages that encode critical
R represents the most 59 region of several HTLV-1 tran-regulatory proteins whose efficient expression might be
scripts including tax, rex, and env (Seiki et al., 1985;dangerous to the cell or the organism (Kozak, 1991;
Figure 3A). In the HTLV-1-R/IL-15 fusion message, this1992).
118 nt element derived from the R region is spliced toTo define the effect of the upstream AUGs of the IL-
the 59 UTR of IL-15 (Figure 3B). Thus, it appears that15 59 UTR on normal IL-15 mRNA translation, two IL-15
the high level expression of IL-15 mRNA by HuT-102 isconstructs were transfected into COS cells, one repre-
due in part to the transcription of a large quantity of asenting wild-type IL-15 message and a second with all
fusion message that involves the IL-15 allele under theupstream AUGs deleted (Bamford et al., 1996). COS
regulatory control of the HTLV-1-R element.cells transfected with an expression construct lacking
A comparative analysis of the 59 UTR of normal andupstream AUGs produced 4- to 5-fold more IL-15 than
HuT-102 IL-15 message provides a partial explanationdid cells transfected with the wild-type construct that
for the more effective translation of IL-15 mRNA ob-retained all ten upstream AUGs. However, it should be
served with HuT-102 cells when compared with acti-noted that in the COS translation system utilized, the
vated monocytes (Figure 4). In the case of HuT-102, thelevels of IL-15 protein generated with either IL-15 con-
introduction of the R element eliminated over 200 nt ofstruct were very low when compared with IL-2, sug-
the IL-15 59 UTR, including 8 of 10 upstream AUGs pres-gesting the probability that additional regulatory events
ent in normal human IL-15 messages that, as discussedexist (Bamford et al., 1996). Therefore, in a search for
above, attenuate translation (Bamford et al., 1995, 1996;additional elements that might impede translation and
secretion, these studies next focused on the unusually Figure 4B). The efficiency of translation of a construct
Immunity
334
Figure 3. Model Defining the Putative Mechanism Underlying the Expression of HTLV-1-R/IL-15 Fusion Message in the Adult T Cell Leukemia
Cell Line HuT-102
(A) The 59 region of many HTLV-1 transcripts consists of a 118 nt element that originates at the cap site of the R region of the virus. This
element of the R region that is the common splice component of HTLV-1 tax, env, and other HTLV-1 transcripts represents the most 59 118
nt of the UTR of these messages.
(B) The predominant IL-15 message produced by HuT-102 is a chimeric mRNA joining 118 nt of the R region of the long terminal repeat of
HTLV-1 and the 59 UTR of IL-15. The genomic structure of human IL-15 shown is deduced from the murine genomic architecture (Anderson
et al., 1995a).
Figure 4. 59 UTR Sequence of Human IL-15 from Normal Cells and HuT-102
(A) 59 UTR of IL-15 as reported (Grabstein et al., 1994) contains ten double underlined ATGs (red) upstream of the initiation ATG, which is
shown in green.
(B) The sequence of the 59 UTR of HTLV-1-R/IL-15 fusion cDNA found in HuT-102. The underlined blue element identifies the 118 nt common
splice sequence from the HTLV-1-R region. Positions 215 and 227 are splice-acceptor sites for R and the double underlined ATGs (red) are
upstream of the initiation ATG that is shown in green. Numbers at right correspond to those of wild-type IL-15 59 UTR (Figure reproduced
with permission from Bamford et al., 1996, Proc. Natl. Acad. Sci. USA, in press).
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encoding the chimeric HTLV-1-R/IL-15 message was such cellular proteins as immunoglobulin heavy-chain
binding protein (BiP) and fibroblast growth factor 2assessed in the COS translation system. COS cells
(McBratney et al., 1993; Vagner et al., 1995). The internaltransfected with this construct produced almost as
initiation process involves the migration of proteins thatmuch IL-15 as those transfected with the construct lack-
usually function in the nucleus inmRNA processing (e.g.,ing all upstream AUGs discussed above and produced
the La autoantigen or the polypyrimidine track bindingsignificantly more IL-15 than cells bearing the construct
protein) into the cytoplasm where they bind toan internalencoding wild-type message. Thus, the dominant factor
ribosome-entry site. The normal elements of the eIF-4Funderlying the effective synthesis and secretion of IL-
initiation complex with the exception of p220 are also15 by the ATL cell line HuT-102 involves a marked in-
involved in this binding event. This process brings ribo-crease in IL-15 mRNA transcription and a moderate in-
somes and other elements of the translational machinerycrease in translation secondary to the production of a
into the vicinity of the authentic start codon (AUG),fusion message joining the HTLV-1-R segment and the
thereby initiating translation. Future studies will be re-59 UTR of IL-15.
quired to determine whether internal initiation or other
mechanisms facilitate IL-15 expression by augmentingHypotheses and Potential Future Directions
its translation in a regulable fashion.for Research Concerning IL-15 mRNA
Translation and Secretion
ConclusionAs a hypothesis, it is proposed that by maintaining a
IL-15 is a novel 14±15 kDa member of the four a helixpool of translationally inactive IL-15 mRNA diverse cells
bundle family of cytokines. Its cDNA encodes a 162 aamight respond rapidly to an intracellular infection by
peptide with a 48 aa leader sequence yielding a 114 aaconverting impeded IL-15 message into effectively
mature protein. In T and NK cells, the high affinity IL-translatable message. The IL-15 produced and secreted
15R includes the IL-2Rb and gc subunits as well as ancould lead to the activation of NK cells that in turn could
IL-15-specific receptor, IL-15Ra, that together with IL-provide an effective host response to the infectious
2Ra defines a new cytokine receptor family. In activatedagent. Nevertheless, it must be emphasized that with
T cells, Jak3 and Jak1 as well as Stat3 and Stat5 partici-the exception of HuT-102 and, to a much lesser extent,
pate in an IL-15 signal transduction pathway. In contrastCV-1/EBNA there is little evidence supporting conver-
with this pattern, mast cells respond to IL-15 using asion of IL-15 mRNA into an efficiently translated mes-
receptor system that does not share elements with thesage. Thus, cell systems (for example, those involving
IL-2R system but apparently involves a novel IL-15RXintracellular pathogens) that are associated with effi-
subunit. In further contrast with T cells, the membrane-cient IL-15 production and secretion should be sought,
proximal events of the mast cell signaling pathway in-since they might be of value indefining regulatory events
clude the tyrosine phosphorylation of Jak2 and an acti-that convert impeded IL-15 message into one that is
vation and nuclear translocation process limited toeffectively translated. In this regard, functional activities
Stat5. The regulation of IL-15 expression differs mark-that were assessed in diverse immunological systems
edly from that of IL-2. IL-15 mRNA is not expressed byand were considered to be IL-15 since they were abro-
normal T cells. However, there is widespread expressiongated by addition of a neutralizing anti-IL-15 antibody
of IL-15 mRNA in a variety of other tissues and cellshave been identified in the cells of the synovial compart-
including placenta, skeletal muscle, kidney, lung, heart,ment of patients with rheumatoid arthritis (McInnes et
fibroblasts, epithelial cells, and activated monocytes.al., 1996), in the supernatants of peripheral blood mono-
Nevertheless, it is difficult to demonstrate meaningful
nuclear cells treated with human Herpes virus-6 (Fla-
quantities of IL-15 in the supernatants of many of these
mand et al., 1996), and in the supernatants of monocyte/
cells, e.g., activated monocytes that contain IL-15
macrophage preparations primed with IFNg and trig-
mRNA, suggesting that there are critical posttranscrip-
gered with high doses of LPS, Bacillus Calmette±Guerlin
tional regulatory events affecting IL-15 expression. IL-
(BCG), Mycobacterium tuberculosis, Toxoplasma gon-
15 message was shown to includea number of elements
dii, or Salmonella choleraesuis (Carson et al., 1995; Doh- that may be impediments to its translation. In particular,
erty et al., 1996; Nishimura et al., 1996). the 59 UTR of normal human IL-15 message is burdened
In noncytokine protein synthesis systems a number with ten upstream AUGs that interfere with efficient IL-
of mechanisms have been identified that are effective 15 translation. Furthermore, the unusually long 48 aa
in the removal of 59 UTR blockade of translation. These leader sequence also interferes with this process. It is
mechanisms may be of relevance to the IL-15 system possible that by storing a pool of translationally inactive
and suggest meaningful directions for future analysis of IL-15 mRNA that cells can readily respond to an intracel-
the IL-15 system in resting cells and those infected with lular infection by unburdening the IL-15 message, trans-
appropriate intracellular pathogens. A common mecha- forming it into one that can be effectively translated into
nism that yielded effective translation involved the re- IL-15 that, in turn, may be active either within the cell
moval of the AUG-burdened 59 UTRs by a splicing event or following its secretion into the biological fluids. Such
(Kozak, 1991; Kozak, 1992). A second potential mecha- secreted IL-15 might facilitate the response to an infec-
nism involves internal initiation of translation (McBratney tious agent by the activation of IL-15R expressing NK
et al., 1993; Vagner et al., 1995). Such internal initiation into effective killer cells.
bypasses the 59 CAP-dependent scanning mechanism
and the translationally attenuating upstream AUGs. Al- Acknowledgment
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